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INTRODUCTION
Barrett’s oesophagus (BE) occurs, according to British guide-
lines, when normal esophageal squamous mucosa is partially 
replaced by metaplastic columnar mucosa.
1 Gastroesophageal 
reflux disease is a major pathogenetic factor for the develop-
ment of BE. BE in turn is the most important risk factor for de-
velopment of oesophageal adenocarcinoma. This cancer has 
a rapidly rising incidence and earlier detection results in im-
proved 5-year survival.
2 Endoscopic surveillance of BE is th-
erefore recommended in order to detect treatable dysplasia 
or cancer at an early stage. 
One of the limitations of current surveillance strategy is the 
difficulty in detecting early neoplastic lesions with conven-
tional white light endoscopy (WLE). Random 4 quadrant bi-
opsies are notorious at missing early neoplasia. Four biopsies 
in any given 2 cm BE segment using the Seattle protocol ap-
proach will only sample 3.5% of the surface of the segment. 
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This can clearly miss any inconspicuous area harboring dys-
plasia or malignancy that may be present in the remaining 
96.5% of the mucosa that is not sampled. The process can be 
laborious not only for the endoscopist but also the nursing 
staff and pathologist. This may partly explain its poor adher-
ence in both the United Kingdom
3 (41%) and the United St-
ates
4 (44-56%).
A new paradigm involving targeted biopsies may enable the 
endoscopist to increase the yield of detecting dysplasia or ma-
lignancy. This approach involves spending time closely in-
specting the mucosa utilizing some of the more novel advanc-
ed endoscopic imaging techniques which will be described 
in greater detail here. 
WHITE LIGHT ENDOSCOPY (WLE)
In order to understand advanced endoscopic imaging te-
chniques it is important we grasp some of the basic tenets on 
conventional WLE. At the present moment, the Prague C&M 
criteria is the best available descriptor for grading the endo-
scopic extent of BE.
5 This criteria includes the assessment of 
the circumferential (C) and maximum (M) extent of the endo-
scopically visualized BE segment in centimeters from the up-
per end of the gastric folds. The Prague criteria have been sh-
own to be reproducible and reliable in different patient popul-
ations.
6,7 
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There are a number of mucosal changes visible on WLE that 
can allow the endoscopist to target biopsies and increase the 
yield of finding neoplasia. Visible lumps in areas of high gr-
ade dysplasia (HGD) suggest a more advanced lesion where 
invasion may be present. Ulcers in Barrett’s esophagus are a 
suspicious finding as they are associated with high rates of oe-
sophageal adenocarcinoma. Ulcers that fail to heal with pro-
ton pump inhibitor therapy are particularly worrying, and 
should be monitored closely for carcinoma. Recently endo-
scopes with the capability of magnification of up to 115 times 
has been introduced to further enhance characterisation of 
the detected lesions.
NARROW BAND IMAGING (NBI)
NBI enhances both the mucosal and the vascular patterns 
of the mucosa. It does this by illuminating the surface of the 
mucosa with 2 narrow wavelengths of light of 415 nm (blue) 
and 540 nm (green). NBI is based on the optical phenomenon 
that the wavelength of light determines the depth of light 
penetration into tissue and the amount of optical scattering. 
Blue light has a short wavelength and only superficially pen-
etrates the mucosa illuminating the detail of the mucosal sur-
face. By contrast, red light has a longer wavelength and pene-
trates a greater depth of the mucosa allowing visualization of 
deeper tissue components. In NBI, the relative intensity of blue 
light is increased and other wavelengths are reduced (green) 
or eliminated (red). This enhances visualization of the superfi-
cial mucosal structures and improves contrast of the vasculature. 
There have been 2 studies looking at the utility of NBI with-
out magnification in the detection of dysplasia in BE. Kara et 
al.
8 found no significant difference in the detection of HGD or 
intramucosal carcinoma (IMC) when high resolution WLE 
was compared to NBI in a randomised cross-over study. Alth-
ough more areas of HGD were detected with NBI compared 
to WLE (4 additional lesions in 3 patients), this did not reach 
statistical significance, given there were only 28 patients en-
rolled in the study. A larger randomized cross-over study com-
pared high resolution NBI with standard resolution WLE in 
67 patients with BE.
9 NBI was found to be superior to standard 
WLE in the detection of dysplasia (57% vs. 43%). In addition, 
more biopsies were taken using standard WLE and random 
four quadrant biopsies compared with NBI-targeted biopsies 
(mean, 8.5 vs. 4.7; p<0.001). The difficulty with this study is 
that the endoscopes with NBI provided higher resolution im-
ages (180 series endoscopes) than the standard WLE (160 se-
ries endoscopes) which may account for some of the improved 
detection rate in the NBI group. In the recently concluded 
‘DON’T BIOPCE’ trial by Sharma and colleagues, patients 
with BE were assessed with WLE, NBI and the probe-based 
CLE system. The investigators found that the addition of NBI 
to WLE improved the sensitivity of dysplasia detection from 
85% to 92%.
10 
A study by Singh et al.
11 comparing still mucosal images 
with histology, found that NBI with optical magnification 
(NBI-Z) was superior to WLE and optical magnification in the 
prediction of dysplastic tissue in BE. However this study did 
not look at the real time benefit of NBI-Z in predicting which 
areas of Barrett’s mucosa to biopsy. 
CHROMOENDOSCOPY
Chromoendoscopy involves the topical application of dyes 
at endoscopy to enhance visualization of the mucosal surface 
architecture. The three most commonly used dyes are acetic 
acid, methylene blue, and indigo carmine. 
Acetic acid causes reversible acetylation of nuclear proteins 
when it is applied to Barrett’s mucosa. This results in transient 
whitening of the tissue with vascular congestion allowing bet-
ter visualisation of the surface mucosal patterns. The whitening 
effect is lost in dysplastic areas earlier than in the surrounding 
mucosa, helping the endoscopist further differentiate be-
tween the two tissues. This effect is transient; lasting 2 to 3 mi-
nutes, so repeated applications of acetic acid may be required. 
Acetic acid-assisted chromoendoscopy has been shown to 
increase the diagnostic yield of finding dysplasia over stan-
dard WLE in 2 studies.
12,13 The larger study
13 consisted of 190 
procedures with acetic acid. There was a correlation between 
the lesions predicted to be neoplastic by acetic acid and those 
diagnosed by histological analysis. There was also a significant 
improvement in the detection of neoplasia using acetic acid 
compared with WLE. Dysplasia or cancer was identified with 
acetic acid with a sensitivity of 95.5% and a specificity of 80%. 
Methylene blue is absorbed actively and homogeneously 
by normal mucosal cells and in a more uneven manner by neo-
plastic cells. The heterogeneous appearance of dysplastic or 
malignant tissue aids in its endoscopic identification.
14 Some 
early trials showed promising results, however a meta-analy-
sis comparing detection rates of neoplasia in BE with methy-
lene blue staining verses random 4 quadrant biopsies showed 
no significant increased yield for the detection of HGD and 
early cancer.
15 For this reason as well as the potential of toxicity 
from oxidative DNA damage to Barrett’s mucosa,
16 methylene 
blue chromoendoscopy has gone out of favour in many centres. 
Indigo carmine is a tissue stain that highlights superficial 
mucosal irregularities by pooling in crevices and depressions in 
and around a lesion. A study of 80 patients with suspicion of 
BE showed that biopsies guided by indigo carmine and magni-
fication endoscopy were able to detect HGD and carcinoma in 
100% of cases. However, this technique was not able to reliably S Costello et al. 
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distinguish low grade dysplasia from non-dysplastic intestinal 
metaplasia.
17
Chromoendoscopy is not widely used in the routine assess-
ment of patients with BE. This is primarily due to the patchy 
evidence as well as practical limitations. These include the 
extra time required both in preparing for and performing the 
procedure. The procedure itself can be messy and some of the 
dyes have safety and toxicity concerns. The outcomes are de-
pendent on the experience and expertise of the individual 
endoscopist. This tends to limit its usefulness outside of terti-
ary/academic referral centers. 
AUTOFLUORESCENCE IMAGING (AFI)
Autofluorescence is the natural emission of light by biolo-
gical substances called fluorophores. When tissues are expos-
ed to short wavelength blue or ultraviolet light, fluorophores 
are excited and emit longer wavelength fluorescent light. Ex-
amples of common fluorophores are collagen, flavins, aroma-
tic amino acids and porphyrins. Normal, metaplastic and dys-
plastic tissues have different concentrations and types of flu-
orophores which in turn emit characteristic patterns of light 
that can help distinguish between tissue types. 
AFI has been shown to be useful in detecting dysplasia
18,19 in 
a number of controlled studies. The technology has also shown 
to aid in the endoscopic resection in BE.
20 Two randomised 
controlled trails have shown a modest improvement in the 
yield using AFI in addition to random 4 quadrant biopsies.
21,22 
However others have shown no benefit of AFI over WLE for 
the detection of dysplasia.
23
One of the major limitations of AFI is the high false positive 
rate of up to 80%.
24 Attempts have been made to address this 
issue by adding NBI to endoscopes with AFI and high resolu-
tion white light capability (trimodal imaging). The false posi-
tive rate was reduced from 81% to 26% with Trimodal imag-
ing.
24 Another study
22 found that trimodal imaging signifi-
cantly increased the number of HGD or malignancies detect-
ed. However the false positive rates were high at 71% and 
when NBI was added 11 HGD lesions were misclassified as 
not suspicious. A community based randomized controlled 
trial in the Netherlands of trimodal imaging did not improve 
the overall detection of dysplasia compared with standard vid-
eo endoscopy. The diagnosis of dysplasia was still being made 
in a significant number of patients by random biopsies.
25 This 
once again demonstrates the difficulty of applying modalities 
such as AFI outside large tertiary referral centres. 
CONFOCAL ENDOMICROSCOPY (CLE)
CLE is an endoscopic modality that allows microscopic ex-
amination of tissues during endoscopy. It provides a similar 
magnification to traditional histology facilitating in vivo as-
sessment of cellular structures. CLE is based on tissue excita-
tion and fluorescence after it is exposed to a low-power blue 
laser light. The laser light is focused at a selected depth in the 
tissue of interest and reflected light is then refocused onto the 
detection system by the same lens. This light passes through a 
small aperture that allows a huge increase in the spatial resolu-
tion of the image. The technique is able to generate a real time 
black and white image from a thin tissue plane. Use of an ex-
ogenous fluorescent dye is required to create the contrast nec-
essary for adequate visualization. The most common contrast 
agent is intravenous fluorescein sodium however topical con-
trast agents can also be used.
26 Intravenous fluorescein has 
been used for decades by ophthalmologists for imaging the 
retinal vasculature and adverse events are rare.
27 Intravenous 
fluorescein highlights the vessels, intra cellular spaces and la-
mina propria but does not stain nuclei. Goblet cell in BE ap-
pear dark on CLE. 
There are two types of confocal endoscopic systems avail-
able. The Pentax system (eCLE; Pentax Co., Tokyo, Japan) uses 
a confocal fluorescence microscope integrated into the distal 
tip of a conventional upper endoscope. The Cellvizio system 
(pCLE; Mauna Kea Technologies, Paris, France) is probe 
based and is inserted through the accessory channel of a tra-
ditional endoscope. The integrated system allows variable 
depth of tissue plane visualization up to 250 µm, while the 
probe system allows fixed-depth tissue plane visualization 
between 70 and 130 µm for standard probes and 55 and 65 
µm for high definition probes.
28 The lateral resolution of the 
probes varies such that the probes with the highest resolution 
(1 μm) have a smaller field of view and the lower resolution 
probes (3.5 μm) have a larger field of view. Confocal probes 
have a limited number of uses, which increases cost. 
Kiesslich et al.
29 first reported the application of eCLE in BE 
and described the endomicroscopic features of normal squa-
mous oesophageal mucosa, BE, BE with dysplasia and cancer. 
Using histopathology as the gold standard, the classification 
system predicted the final diagnosis of BE with a sensitivity 
of 98%, specificity of 94% and accuracy of 97.5%.
29 A blinded, 
randomized crossover trial for eCLE in BE
30 looked at 23 pa-
tients undergoing surveillance and 16 patients with non-lo-
calized neoplasia. They underwent eCLE and standard en-
doscopy with random biopsies according to the Seattle 
protocol, in a randomized order. During eCLE, microscopic im-
ages were acquired, but only targeted mucosal biopsies were 
taken if the CLE imaging suggested neoplasia. Compared 
with standard endoscopy, eCLE with targeted mucosal biop-
sies increased the yield in subjects with unlocalized neoplasia 
from 17% to 34%. eCLE also led to 59% fewer biopsies to 90  Clin Endosc 2011;44:87-92
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achieve a comparable overall diagnosis. In subjects undergo-
ing routine endoscopic surveillance, there were significantly 
less biopsies taken during CLE. This was highlighted by the 
observation that 65% of subjects undergoing surveillance had 
normal CLE imaging and so no mucosal biopsies were taken. 
In another study, eCLE has been shown to assist in allowing 
targeted EMR in subjects with unlocalized neoplasia in Bar-
rett’s mucosa.
31
One of the first studies of probe based endomicroscopy 
(pCLE) looked at images from 23 subjects using pCLE to 
distinguish between dysplastic and nondysplastic BE.
32 The 
in vivo sensitivity for detecting BE neoplasia was 75% with a 
specificity of 89% to 91%. The positive predictive value for BE 
neoplasia was 44% and the negative predictive value was 98% 
using pCLE. A more recent study
33 involved 63 patients who 
had an overall prevalence of HGD or cancer of 83% which was 
thought to be more representative of general gastroentero-
logical practice. In this setting the sensitivity was poor at only 
12% with a specificity 95%. The pCLE appears to have a lower 
sensitivity in detecting HGD and malignancy in BE compar-
ed to eCLE. This may be because the probe based system can 
have a lower resolution, smaller field of view and more motion 
artifact depending on the probe used. 
CLE has shown promise as a tool that may help endoscopist 
to target biopsies in BE. It is not yet clear at this stage whether 
it can replace biopsies. The technology is expensive and pro-
cedure itself can also be time consuming. CLE requires endos-
copists expert in the technical skills to obtain the images and 
with the knowledge to interpret them. 
FUTURE OUTLOOK: OTHER  
TECHNOLOGIES
There are a number of other technologies being developed 
for the detection of neoplasia in patients with BE. 
Several biomarkers of oesophageal adenocarcinoma risk are 
currently under investigation. Loss of heterozygosity of speci-
fic genes and nuclear DNA abnormalities (aneuploidy and te-
traploidy) have been the mostly widely investigated.
34 Methyl-
ation of the genes p16, HPP1, and RUNX3 have been shown to 
predict future malignant transformation in patients with BE.
35,36 
These and other biomarkers could possibly be used in the fu-
ture to stratify the patients with BE into groups at particular risk 
of neoplasia who may benefit most from surveillance. None 
of the biomarkers have been validated for clinical use at this 
time, however. 
Optical coherence tomography (OCT) uses a coherent short 
wavelength of light to provide real time cross sectional imag-
ing of the oesophageal mucosa. It can identify pit patterns and 
glandular architecture. OCT has been shown to detect HGD 
or IMC with a sensitivity of 83% and specificity of 75%.
37 It is 
however not widely available and is limited by its inability to 
assess large surface areas. 
Spectroscopic modalities use the interaction between light 
and tissue to provide information about the nanoscale archi-
tecture of the oesophageal epithelium.
38 Light scattering spec-
troscopy can elicit information about a cell nuclei and quantify 
differences between dysplastic and non-dysplastic tissue in BE.
39 
A much lower cost screening tool for BE is being developed 
called the capsule sponge oesophageal cytology. This consists 
of a cytology sponge that is compressed within a gelatin cap-
sule attached to a string. The capsule is swallowed and expands 
in the stomach prior to being pulled back up the oesophagus 
by the string. The sponge collects oesophageal mucosal cells 
that then undergo molecular biological identification. Trefoil 
factor 3 is strongly expressed in Barrett’s mucosa. A pilot study 
found this screening test to have a sensitivity of 78% and a spe-
cificity of 94% for BE.
40 In the future molecular markers may 
become available to screen for dysplasia or malignancy. 
CONCLUSIONS 
The aim of endoscopic surveillance in patients with BE is to 
identify neoplastic lesions that can be targeted with biopsy and 
excised with endoscopic resection techniques. This approach 
can avoid the need for oesophagectomy which can have signifi-
cant morbidity and mortality. A detailed clinical assessment, 
followed by a careful endoscopic examination of the oesoph-
agus with high resolution WLE and targeted biopsies follow-
ed by random 4 quadrant biopsies still remains the standard 
of care for patients with BE. The examination however can be 
enhanced by the addition of more advanced imaging modal-
ities such as NBI, AFI, and chromoendoscopy. These techni-
ques have shown promise to help delineate lesions found at 
WLE and to increase the yield of detecting neoplasia. 
There are a number of factors that may limit the widespread 
uptake of some of these advanced endoscopic technologies. 
The ease of use, learning curve, availability and cost are barri-
ers at present to some of these modalities. Most studies of 
these techniques have been performed in expert tertiary re-
ferral centers with expert endoscopists in the use of a partic-
ular modality. The results of these trials may not be applica-
ble to routine community practice in many instances. 
Oesophageal adenocarcinoma has a bleak prognosis. Sur-
veillance of its precursor lesion, BE, has many limitations at 
present. However, advances in endoscopic imaging have the 
potential to improve the yield and efficiency of BE surveill-
ance with the ultimate aim of reducing the incidence and mor-
tality and curb the rising trend of oesophageal adenocarcino-
ma in our patients.S Costello et al. 
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